272 related articles for article (PubMed ID: 27604143)
21. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
22. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract][Full Text] [Related]
23. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
[TBL] [Abstract][Full Text] [Related]
25. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
26. The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence-associated epigenomic remodeling.
Tanaka H; Igata T; Etoh K; Koga T; Takebayashi SI; Nakao M
Aging Cell; 2020 Jul; 19(7):e13173. PubMed ID: 32573059
[TBL] [Abstract][Full Text] [Related]
27. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
[TBL] [Abstract][Full Text] [Related]
28. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
Zhu L; Yu CL; Zheng Y
Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
[TBL] [Abstract][Full Text] [Related]
29. Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
Zheng Y; Fornelli L; Compton PD; Sharma S; Canterbury J; Mullen C; Zabrouskov V; Fellers RT; Thomas PM; Licht JD; Senko MW; Kelleher NL
Mol Cell Proteomics; 2016 Mar; 15(3):776-90. PubMed ID: 26272979
[TBL] [Abstract][Full Text] [Related]
30. NSD2 activates the E2F transcription factor 1/Y-box binding protein 2 axis to promote the malignant development of oral squamous cell carcinoma.
Zhang L; Hu G
Arch Oral Biol; 2022 Jun; 138():105412. PubMed ID: 35364436
[TBL] [Abstract][Full Text] [Related]
31. ISWI chromatin remodeling complexes recruit NSD2 and H3K36me2 in pericentromeric heterochromatin.
Goto N; Suke K; Yonezawa N; Nishihara H; Handa T; Sato Y; Kujirai T; Kurumizaka H; Yamagata K; Kimura H
J Cell Biol; 2024 Aug; 223(8):. PubMed ID: 38709169
[TBL] [Abstract][Full Text] [Related]
32. PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage.
Zhang J; Lee YR; Dang F; Gan W; Menon AV; Katon JM; Hsu CH; Asara JM; Tibarewal P; Leslie NR; Shi Y; Pandolfi PP; Wei W
Cancer Discov; 2019 Sep; 9(9):1306-1323. PubMed ID: 31217297
[TBL] [Abstract][Full Text] [Related]
33. NSD2 is downregulated in T2DM and promotes β cell proliferation and insulin secretion through the transcriptionally regulation of PDX1.
Shi S; Zhao L; Zheng L
Mol Med Rep; 2018 Sep; 18(3):3513-3520. PubMed ID: 30066931
[TBL] [Abstract][Full Text] [Related]
34. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
35. Cancers and the NSD family of histone lysine methyltransferases.
Morishita M; di Luccio E
Biochim Biophys Acta; 2011 Dec; 1816(2):158-63. PubMed ID: 21664949
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
37. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
38. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
[TBL] [Abstract][Full Text] [Related]
39. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.
Toyokawa G; Cho HS; Masuda K; Yamane Y; Yoshimatsu M; Hayami S; Takawa M; Iwai Y; Daigo Y; Tsuchiya E; Tsunoda T; Field HI; Kelly JD; Neal DE; Maehara Y; Ponder BA; Nakamura Y; Hamamoto R
Neoplasia; 2011 Oct; 13(10):887-98. PubMed ID: 22028615
[TBL] [Abstract][Full Text] [Related]
40. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]